INSULCLOUD

Their core work

INSULCLOUD is a Madrid-based health technology SME that developed INSULCLOCK, a digital platform for empowering patients and clinicians to control drug dosage in chronic diseases — almost certainly focused on insulin management given the company name and project branding. Their core product combines connected device hardware with cloud-based software to improve dosage precision and patient adherence in conditions requiring ongoing medication management. They successfully progressed through the full Horizon 2020 SME Instrument cycle, moving from a €50,000 Phase 1 feasibility study in 2015 to a €1.037M Phase 2 full-scale innovation project in 2016, which signals validated commercial potential and execution capability. Their work sits at the intersection of chronic disease management, digital health, and IoT-connected medical devices.

What they specialise in

How they've shifted over time

INSULCLOUD's H2020 trajectory is a textbook SME Instrument scale-up story compressed into two years: a Phase 1 feasibility check in 2015 (€50K, classified under ICT) confirmed their concept, and a Phase 2 full innovation project in 2016–2018 (€1M+, classified under Innovation and SME) brought it to market-ready stage. The shift in pillar classification — from P2-ICT in Phase 1 to P3-Health in Phase 2 — suggests their framing matured from a technology pitch to a health outcome pitch as they approached commercialization. No keyword data is available to track thematic granularity, but the structural evidence points to a single-product company that deepened rather than broadened its focus during this period.

INSULCLOUD appears to have been in a commercialization push through 2018; whether they successfully exited to market or pivoted since then is unknown from available data, making them an interesting but uncertain prospect for future collaboration.

How they like to work

INSULCLOUD operates exclusively as a solo coordinator — both of their projects were self-led with no recorded consortium partners, which is standard for the SME Instrument funding scheme they used. This means they have no established track record of consortium collaboration and have built their EU project experience entirely around their own product development rather than network-building. For a potential partner, this suggests a company that is product-focused and self-sufficient, but which may lack the multi-partner coordination experience expected in larger Horizon Europe calls.

INSULCLOUD has zero recorded consortium partners across their entire H2020 history, which is expected given the solo-applicant nature of the SME Instrument scheme they used. Their network footprint is entirely Spain-based with no documented international research or industry connections through EU funding.

What sets them apart

INSULCLOUD is one of very few SMEs to have secured the full SME Instrument Phase 1 + Phase 2 progression for the same product, which signals that independent EU evaluators validated both the technical concept and the commercial plan — a meaningful quality signal in a competitive scheme. Their positioning at the crossroads of chronic disease management, cloud connectivity, and patient empowerment places them in a high-growth segment of digital health, particularly relevant for diabetes and cardiovascular disease management markets. For a consortium builder needing a validated health tech SME with a market-tested product narrative, INSULCLOUD offers credibility as a commercial end-user or exploitation partner.

Highlights from their portfolio

• INSULCLOCK (Phase 2)
  The largest project at €1.037M represents a successful full-scale EU SME Instrument Phase 2 award — a highly competitive grant that fewer than 5% of applicants receive — validating the commercial and technical maturity of their drug dosage control platform.
• INSULCLOCK (Phase 1)
  The €50K Phase 1 feasibility study, completed in 2015, is notable as the launchpad that secured the much larger Phase 2 award, demonstrating a deliberate and successful EU funding strategy for a single product.